A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib | Blood | American Society of Hematology
You do not currently have access to this content.
Related Articles
Boosting CAR T-Cell Efficacy by Blocking Proteasomal Degradation of Membrane Antigens
Key Points. BCMA antigen expression is controlled by the ubiquitin-proteasome system in a p97-dependent manner at the plasma membraneElevation of BCMA cell
Sequential BCMA CAR-T Cell Therapy in Refractory Multiple Myeloma
Key Points. Sequential treatment with commercially available BCMA-directed CAR-T therapy in refractory myeloma is safe and efficaciousDuration of response
Landscape and clinicopathologic features of RAS pathway mutations in chronic myelomonocytic leukemia
Key Points. Mutations in distinct RAS-pathway genes have unique clonal architecture and cooperate with other genomic events to drive outcomes in CMML.Refin
Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis
Abstract. Bispecific antibodies, a novel immunotherapy with promising efficacy against multiple myeloma, form immune synapses between T-cell surface marker CD3
Suboptimal Humoral and Cellular Immune Response to SARS-CoV-2 RNA Vaccination in Myeloma Patients Is Associated with Anti-CD38 and BCMA-Targeted Treatment
Abstract. Background: Multiple myeloma (MM) patients are immunocompromised due to defects in humoral/cellular immunity and immunosuppressive therapy. Repor
Shingles Occurs in Only 0.5% of Myeloma Patients on Any Dose of Antiviral Prophylaxis
Abstract. Background: CDC estimates that approximately 30% of persons in the U.S. will experience shingles during their lifetimes (http://www.cdc.gov/shing
Tackling Early Morbidity and Mortality in Myeloma (TEAMM): Assessing the Benefit of Antibiotic Prophylaxis and Its Effect on Healthcare Associated Infections in 977 Patients
Abstract. BackgroundTEAMM (Tackling EArly Morbidity and Mortality in Myeloma) was a randomised, double-blind, placebo-controlled multi-centre phase III cli
Uncovering the Blind Spot of Clinical Trials: First Report of Baseline Characteristics of Newly Diagnosed (ND) and Relapsed/Refractory (RR) Multiple Myeloma (MM) Patients (Pts) in Insight-MM, a Global, Prospective, Observational Study
Abstract. BackgroundThe advance of novel therapeutics has resulted in a significant improvement in outcomes for MM pts. Median progression-free survival (P